MDxHealth (NASDAQ:MDXH) Trading 0.5% Higher – Should You Buy?

MDxHealth SA (NASDAQ:MDXH) shot up 0.5% during trading on Monday . The company traded as high as $2.20 and last traded at $2.19. 57,635 shares changed hands during trading, a decline of 36% from the average session volume of 90,010 shares. The stock had previously closed at $2.18.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of MDxHealth to a “hold” rating in a report on Saturday, May 24th.

MDxHealth Stock Performance

The firm’s fifty day simple moving average is $2.06 and its 200 day simple moving average is $1.87. The company has a market capitalization of $103.56 million, a price-to-earnings ratio of -1.90 and a beta of 1.31. The company has a debt-to-equity ratio of 13.81, a current ratio of 2.00 and a quick ratio of 1.92.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The company had revenue of $24.29 million during the quarter, compared to analysts’ expectations of $22.62 million. MDxHealth had a negative return on equity of 492.11% and a negative net margin of 41.02%. On average, sell-side analysts forecast that MDxHealth SA will post -1.15 EPS for the current year.

Institutional Investors Weigh In On MDxHealth

A number of institutional investors have recently bought and sold shares of MDXH. AWM Investment Company Inc. raised its holdings in shares of MDxHealth by 10.6% in the first quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company’s stock valued at $7,414,000 after buying an additional 499,992 shares during the last quarter. Delta Investment Management LLC grew its position in shares of MDxHealth by 459.1% in the 1st quarter. Delta Investment Management LLC now owns 190,100 shares of the company’s stock valued at $270,000 after purchasing an additional 156,100 shares during the period. Perkins Capital Management Inc. boosted its position in MDxHealth by 20.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company’s stock worth $1,678,000 after acquiring an additional 198,000 shares during the last quarter. Castleview Partners LLC acquired a new position in MDxHealth during the 1st quarter worth approximately $48,000. Finally, FAS Wealth Partners Inc. boosted its holdings in shares of MDxHealth by 49.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock valued at $58,000 after buying an additional 8,100 shares during the last quarter.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.